Futura Medical "absolutely delighted" with US commercialisation agreement
London, UK
|
July 19, 2023 10:52 AM Eastern Daylight Time
Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder speaks to Thomas Warner from Proactive London after announcing the signing of an agreement with Haleon to market Futura's topical, gel-based erectile dysfunction treatment MED3000. Barder says he's absolutely delighted with the agreement, which gives Futura access to the world's largest market for erectile dysfunction treatments.
He gives a brief overview of the agreement, highlighting a $4 million upfront payment and milestone payments ranging from $5 million to $45 million. Barder emphasised the achievability of these milestones and mentioned that a royalty on all sales was also part of the agreement.
In related news, Futura Medical announced a change in leadership with Non-Executive Chairman John Clarke stepping down to be succeeded by existing Non-Executive board member, Jeff Needham. Barder says that Needham has "real, relevant experience as we look to launch in the biggest market in the world with MED3000."
Contact Details
Proactive UK Ltd
+44 20 7989 0813
